

Servier celebrates its 60th anniversary in Spain

Paris, France, 17th December 2018 - International independent pharmaceutical company Servier is celebrating its 60th anniversary in Spain. During his visit to Madrid, Olivier Laureau, CEO of Servier, emphasised the strategic importance of the Spanish market for Servier and the Group's wish to continue to invest in the long term.

Historic roots

Since the creation of its subsidiary in Madrid in 1957, Servier has developed its activities in four sectors: sales, launched in 1957, pharmaceutical production in Madrid which began in 1982, chemical production in Toledo, launched in 1978, and the Madrid International Centre for Therapeutic Research (ICTR), set up in 1984.

"Today, Spain is one of the few countries, along with France and Hungary, to offer these four sectors of activity sectors", said Olivier Laureau at a reception hosted by Mr. Yves Saint-Geours, French Ambassador to Spain, on 11th December. *"Our teams in Madrid and Toledo work continuously with passion and commitment to meet patient needs. Our drugs currently treat 800,000 patients in Spain every year",* he added.

Every day, the company's 348 employees demonstrate their commitment. These sectors of activity are being constantly improved in terms of quality, cost and time. During the last 60 years, the subsidiary has developed an increasingly more efficient, more agile and more proactive organisational structure in order to stimulate innovation and offer patients new therapeutic solutions.

Major contributions from Servier Spain to the Group's development

In October 2018, Servier Spain registered the second consecutive year of strong growth and passed the symbolic milestone of 60 M EUR for its 60th anniversary, a turnover that had not been achieved since 2014. Growth is due to several successes: its two spearheads in cardiology - Carevalan and Lipocomb - , its position in the treatment of mental health conditions, due to the reboosting of Valdoxan and the successful launch of Enzude; the considerable success of Daflon 500, now on the OTC market¹, while in oncology, the successful launches of Lonsurf and Pixuvri strengthened by the integration of Oncaspar and Onivyde, are keys to the future.

Servier in Spain - 2017-2018 figures

- 61.3 M EUR: subsidiary's turnover
- 348 employees
- 20 products marketed in Spain of which 7 are manufactured in the Madrid facility.
- 8.4 million boxes produced
- 246 tonnes of chemicals produced in Toledo per year (all exported)
- 23 R&D studies conducted

¹ An over-the-counter or **OTC** drug or medicine, also called a non-prescription drug, can be sold directly to a consumer without a prescription from a healthcare professional.



“With 20 medicines available to medical professionals and patients in Spain and a total production of 8.4 million boxes, 20 products marketed locally, mainly in cardiology, and an expanding portfolio in oncology, the Spanish subsidiary’s turnover in 2017-2018 amounted to 61.3 million euros”, added Olivier Laureau.

Increased local investment

Olivier Laureau also took the opportunity to reiterate his commitment to stepping up investments in Spain, considered a growth market in the Group’s strategy. In 2017-2018, the Group thus invested 10 M EUR in Research & Development recognised by the Spanish authorities through the Profarma qualification.

Today, Servier has 23 R&D studies underway, conducted by its International Centre for Therapeutic Research (ICTR), which makes Spain one of the key contributors to the development of the Group’s portfolio. The Toledo production facility plays a very active role in the company’s R&D processes. In close collaboration with the facility in Bolbec, France, the Toledo site works on future drugs, especially in oncology, one of the Group’s priority lines of research

“It is thanks to our policy to actively encourage research and innovation, and through the Profarma programme in particular, that we can develop our scientific and industrial activities in the country, to the benefit of patients”, explained Régis Fedrigo, General Manager of Servier Spain subsidiary. “We are very proud to receive the “Muy Buena” qualification, which has been consistently renewed for more than 10 years. This qualification is a mark of Servier’s ongoing commitment to Spain”.

The Profarma programme was launched by the Spanish government to stimulate R&D and innovation in the pharmaceutical industry. A pharmaceutical company’s inclusion in the programme and resulting qualification depend on its contribution to the country’s scientific development. This is assessed by the amount and quality of its R&D investments, its contribution to the growth of overall employment in research and industry and by industrial investments and the trade balance. Servier Spain has been a participant in the programme since 1994.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (princeps drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

More information: www.servier.com

Follow us on Social Media:   

Press contacts:

Sonia Marques : media@servier.com – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Karine Bousseau : media@servier.com – Tel. +33 (0)1 55 72 60 37 / + 33 (0) 6 49 92 16 05